COSCIENS BIOPHARMA INC (CSCI.CA) Fundamental Analysis & Valuation

TSX:CSCI • CA22112H1010

Current stock price

2.74 CAD
+0.06 (+2.24%)
Last:

This CSCI.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CSCI.CA Profitability Analysis

1.1 Basic Checks

  • In the past year CSCI has reported negative net income.
  • CSCI had a negative operating cash flow in the past year.
  • In the past 5 years CSCI always reported negative net income.
  • In the past 5 years CSCI always reported negative operating cash flow.
CSCI.CA Yearly Net Income VS EBIT VS OCF VS FCFCSCI.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10M -20M

1.2 Ratios

  • CSCI has a Return On Assets (-48.33%) which is in line with its industry peers.
  • With a Return On Equity value of -269.60%, CSCI perfoms like the industry average, outperforming 52.17% of the companies in the same industry.
Industry RankSector Rank
ROA -48.33%
ROE -269.6%
ROIC N/A
ROA(3y)-35.55%
ROA(5y)-31.54%
ROE(3y)-134.16%
ROE(5y)-96.35%
ROIC(3y)N/A
ROIC(5y)N/A
CSCI.CA Yearly ROA, ROE, ROICCSCI.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 -400

1.3 Margins

  • Looking at the Gross Margin, with a value of 35.30%, CSCI is in the better half of the industry, outperforming 69.57% of the companies in the same industry.
  • In the last couple of years the Gross Margin of CSCI has remained more or less at the same level.
  • CSCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-28.9%
GM growth 5Y0.1%
CSCI.CA Yearly Profit, Operating, Gross MarginsCSCI.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. CSCI.CA Health Analysis

2.1 Basic Checks

  • CSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CSCI has been increased compared to 1 year ago.
  • CSCI has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for CSCI is higher compared to a year ago.
CSCI.CA Yearly Shares OutstandingCSCI.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M
CSCI.CA Yearly Total Debt VS Total AssetsCSCI.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • CSCI has an Altman-Z score of -1.93. This is a bad value and indicates that CSCI is not financially healthy and even has some risk of bankruptcy.
  • CSCI has a Altman-Z score (-1.93) which is in line with its industry peers.
  • A Debt/Equity ratio of 0.50 indicates that CSCI is somewhat dependend on debt financing.
  • CSCI has a Debt to Equity ratio of 0.50. This is comparable to the rest of the industry: CSCI outperforms 52.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF N/A
Altman-Z -1.93
ROIC/WACCN/A
WACC8.44%
CSCI.CA Yearly LT Debt VS Equity VS FCFCSCI.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

2.3 Liquidity

  • CSCI has a Current Ratio of 3.18. This indicates that CSCI is financially healthy and has no problem in meeting its short term obligations.
  • CSCI has a better Current ratio (3.18) than 73.91% of its industry peers.
  • CSCI has a Quick Ratio of 2.82. This indicates that CSCI is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of CSCI (2.82) is better than 73.91% of its industry peers.
Industry RankSector Rank
Current Ratio 3.18
Quick Ratio 2.82
CSCI.CA Yearly Current Assets VS Current LiabilitesCSCI.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. CSCI.CA Growth Analysis

3.1 Past

  • CSCI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.22%, which is quite impressive.
  • The Revenue for CSCI has decreased by -21.79% in the past year. This is quite bad
  • CSCI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.17% yearly.
EPS 1Y (TTM)38.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68%
Revenue 1Y (TTM)-21.79%
Revenue growth 3Y10.22%
Revenue growth 5Y15.17%
Sales Q2Q%-46.84%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CSCI.CA Yearly Revenue VS EstimatesCSCI.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
CSCI.CA Yearly EPS VS EstimatesCSCI.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2021 2022 2023 2024 0 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

0

4. CSCI.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CSCI. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CSCI.CA Price Earnings VS Forward Price EarningsCSCI.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CSCI.CA Per share dataCSCI.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CSCI.CA Dividend Analysis

5.1 Amount

  • CSCI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CSCI.CA Fundamentals: All Metrics, Ratios and Statistics

COSCIENS BIOPHARMA INC

TSX:CSCI (4/21/2026, 7:00:00 PM)

2.74

+0.06 (+2.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-15
Earnings (Next)05-11
Inst Owners8.08%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap8.71M
Revenue(TTM)7.50M
Net Income(TTM)-10.36M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.85
P/FCF N/A
P/OCF N/A
P/B 1.66
P/tB 1.66
EV/EBITDA N/A
EPS(TTM)-4.47
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-3.94
FCFYN/A
OCF(TTM)-3.64
OCFYN/A
SpS3.22
BVpS1.65
TBVpS1.65
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -48.33%
ROE -269.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.3%
FCFM N/A
ROA(3y)-35.55%
ROA(5y)-31.54%
ROE(3y)-134.16%
ROE(5y)-96.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-28.9%
GM growth 5Y0.1%
F-Score3
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.43%
Cap/Sales 9.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.18
Quick Ratio 2.82
Altman-Z -1.93
F-Score3
WACC8.44%
ROIC/WACCN/A
Cap/Depr(3y)60.57%
Cap/Depr(5y)123.1%
Cap/Sales(3y)10.54%
Cap/Sales(5y)8.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-21.79%
Revenue growth 3Y10.22%
Revenue growth 5Y15.17%
Sales Q2Q%-46.84%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y41.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.84%
OCF growth 3YN/A
OCF growth 5YN/A

COSCIENS BIOPHARMA INC / CSCI.CA Fundamental Analysis FAQ

What is the fundamental rating for CSCI stock?

ChartMill assigns a fundamental rating of 2 / 10 to CSCI.CA.


What is the valuation status for CSCI stock?

ChartMill assigns a valuation rating of 0 / 10 to COSCIENS BIOPHARMA INC (CSCI.CA). This can be considered as Overvalued.


Can you provide the profitability details for COSCIENS BIOPHARMA INC?

COSCIENS BIOPHARMA INC (CSCI.CA) has a profitability rating of 1 / 10.


How financially healthy is COSCIENS BIOPHARMA INC?

The financial health rating of COSCIENS BIOPHARMA INC (CSCI.CA) is 3 / 10.